International Clinical Trial: Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07205081) titled 'Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Attovia Therapeutics Inc

Condition: Normal Volunteers Atopic Dermatitis (AD) Atopic Eczema Atopic Eczema/Dermatitis (Non-Specific)

Intervention: Drug: ATTO-3712

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 2025

Target Sample...